[
  {
    "ts": null,
    "headline": "GILD Wins Approval for Twice-Yearly HIV Prevention Shot in the EU",
    "summary": "Gilead secures EU approval for twice-yearly HIV prevention shot Yeytuo, backed by strong trial data and expanded market protection.",
    "url": "https://finnhub.io/api/news?id=75d9b24c0cd17c7275aa5e8b9b7aa3be07b187254ade510a67a413895da9bcca",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756215600,
      "headline": "GILD Wins Approval for Twice-Yearly HIV Prevention Shot in the EU",
      "id": 136526772,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Gilead secures EU approval for twice-yearly HIV prevention shot Yeytuo, backed by strong trial data and expanded market protection.",
      "url": "https://finnhub.io/api/news?id=75d9b24c0cd17c7275aa5e8b9b7aa3be07b187254ade510a67a413895da9bcca"
    }
  },
  {
    "ts": null,
    "headline": "Is There Now an Opportunity in Pfizer After FDA Covid Vaccine Review for Children?",
    "summary": "Thinking about what to do with your Pfizer shares? You are definitely not alone, especially as sentiment around the stock feels conflicted. Over the past week, Pfizer slid a modest 0.7%, and for the year so far, it is down 5.5%. But here is where it gets interesting: the stock did manage to gain 1.4% over the past 30 days. Even with a 3-year decline of 35.4%, recent price action hints that investors are weighing new risks and opportunities. In other words, Pfizer is not just treading water;...",
    "url": "https://finnhub.io/api/news?id=225c9c289c3b805ba5e4f2ae3e9f3eca63c1e619af759877e3ff71213087374f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756203146,
      "headline": "Is There Now an Opportunity in Pfizer After FDA Covid Vaccine Review for Children?",
      "id": 136524007,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Thinking about what to do with your Pfizer shares? You are definitely not alone, especially as sentiment around the stock feels conflicted. Over the past week, Pfizer slid a modest 0.7%, and for the year so far, it is down 5.5%. But here is where it gets interesting: the stock did manage to gain 1.4% over the past 30 days. Even with a 3-year decline of 35.4%, recent price action hints that investors are weighing new risks and opportunities. In other words, Pfizer is not just treading water;...",
      "url": "https://finnhub.io/api/news?id=225c9c289c3b805ba5e4f2ae3e9f3eca63c1e619af759877e3ff71213087374f"
    }
  }
]